Subscribe to RSS
Synthesis of MB06322
Q. Dang, S. R. Kasibhatla, K. R. Reddy, T. Jiang, M. R. Reddy, S. C. Potter, J. M. Fujitaki, P. D. van Poelje, J. Huang, W. N. Lipscomb, M. D. Erion*
Metabasis Therapeutics, La Jolla and Harvard University, Cambridge, USA
19 March 2008 (online)
MB06322 is an orally available phosphonate diamide prodrug to compound D, a potent inhibitor of fructose-1,6-bisphosphatase (FBPase). FBPase is a rate-limiting enzyme in glucose production whose inhibition offers a potential treatment for type 2 diabetes.